1. Central and peripheral nervous system toxicity of common chemotherapeutic agents

   • Chrissa Sioka
   • Athanassios P. Kyritsis

   Mini Review 25 November 2008 Pages: 761 - 767

2. Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79

   • Teresa Kosakowska-Cholody
   • Wieslaw M. Cholody
   • Brian I. Carr

   Original Article 19 July 2008 Pages: 769 - 778

   

3. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature

   • Gil Bar-Sela
   • Nissim Haim

   Original Article 19 July 2008 Pages: 779 - 782

4. Dependence on PI3K/Akt signaling for malignant rhabdoid tumor cell survival

   • Kristen Foster
   • Yong Wang
   • Cynthia Wright

   Original Article 19 July 2008 Pages: 783 - 791

   

5. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551

   • Nancy L. Bartlett
   • Jeffrey L. Johnson
   • For the Cancer and Leukemia Group B

   Original Article 23 July 2008 Pages: 793 - 798

   

6. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin

   • Kurt Van der Speeten
   • O. A. Stuart
   • P. H. Sugarbaker

   Original Article 25 July 2008 Pages: 799 - 805

   

7. Characterization of kinase suppressor of Ras-1 expression and anticancer drug sensitivity in human cancer cell lines

   • Scott M. Stoeger
   • Kenneth H. Cowan

   Original Article 26 July 2008 Pages: 807 - 818

   

8. A multiple-center phase II study of biweekly oxaliplatin and tegafur–uracil/leucovorin for chemonaive patients with advanced gastric cancer

   • Jen-Shi Chen
   • Kun-Ming Rau
   • Ruey-Ho Kao

   Original Article Open access 29 July 2008 Pages: 819 - 825

9. A model-based approach to the in vitro evaluation of anticancer activity

   • Francesca Del Bene
   • Massimiliano Germani
   • Maurizio Rocchetti

   Original Article 29 July 2008 Pages: 827 - 836

   

10. Role of RNase L in apoptosis induced by 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl)cytosine

    • Tomoharu Naito
    • Tatsushi Yokogawa
    • Hye-Sook Kim

    Original Article 31 July 2008 Pages: 837 - 850

    

11. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma

    • Joanna M. Brell
    • Smitha S. Krishnamurthi
    • Scot C. Remick

    Original Article 01 August 2008 Pages: 851 - 857

    

12. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804

    • Richard M. Stone
    • Kathleen A. Donohue
    • for the Cancer and Leukemia Group B

    Original Article 01 August 2008 Pages: 859 - 864

    

13. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer

    • Tomo Osako
    • Yoshinori Ito
    • Kiyohiko Hatake

    Original Article 01 August 2008 Pages: 865 - 871

    

14. Protective effect of aged garlic extract (AGE) on the apoptosis of intestinal epithelial cells caused by methotrexate

    • Tiesong Li
    • Kousei Ito
    • Toshiharu Horie

    Original Article 02 August 2008 Pages: 873 - 880

    

15. The Werner’s syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds

    • Federico Innocenti
    • Snezana Mirkov
    • Mark J. Ratain

    Original Article 02 August 2008 Pages: 881 - 887

    

16. Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases

    • Andrew G. Jobson
    • Elaine Willmore
    • Caroline A. Austin

    Original Article 05 August 2008 Pages: 889 - 901

    

17. A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors

    • Claire F. Verschraegen
    • Keith Skubitz
    • Fred B. Oldham

    Original Article 06 August 2008 Pages: 903 - 910

    

18. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population

    • Zhao-Hui Huang
    • Dong Hua
    • Li-Hua Li

    Original Article 15 August 2008 Pages: 911 - 918

    

19. Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials

    • Hei-Cheul Jeung
    • Sun Young Rha
    • Hyun Cheol Chung

    Original Article 20 August 2008 Pages: 919 - 927

    

20. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma

    • Ji Eun Uhm
    • Joon Oh Park
    • Ho Yeong Lim

    Original Article 23 August 2008 Pages: 929 - 935

    

21. Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer

    • Mario Campone
    • Maria Blasinska-Morawiec
    • Maud Brandely

    Original Article 27 August 2008 Pages: 937 - 943

    

22. A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy

    • Janet S. Graham
    • Stephen Falk
    • T. R. Jeffry Evans

    Clinical Trial Report 25 July 2008 Pages: 945 - 952

    

23. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial

    • Sibylle Loibl
    • Caroline Murmann
    • Gunter von Minckwitz

    Clinical Trial Report 21 August 2008 Pages: 953 - 958

    

24. Intracellular disposition of fludarabine triphosphate in human natural killer cells

    • Erica L. Woodahl
    • Joanne Wang
    • Jeannine S. McCune

    Short Communication 10 September 2008 Pages: 959 - 964

    

25. A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer

    • Lorenzo Fornaro
    • G. Masi
    • A. Falcone

    Short Communication 07 October 2008 Pages: 965 - 969

    

26. Acute hepatic failure following monotherapy with sunitinib for ovarian cancer

    • A. Taran
    • A. Ignatov
    • J. Bischoff

    Letter to the Editor 21 August 2008 Pages: 971 - 972